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Human immunodeficiency virus (HIV)-1 is an inflammatory disease that disrupts central 
nervous system (CNS) function as viral proteins, such as transactivator of transcription (Tat), 
induce inflammatory responses leading to neuronal damage. This neurodegeneration translates to 
behavioral dysregulation such as motivational deficits which are commonly seen in HIV-1 
infected individuals. With the emergence of the endocannabinoid (eCB) system as an area for 
therapeutics combatting neurodegenerative disorders, MJN110, a monoacylglycerol lipase 
(MAGL) inhibitor is evaluated in this study. In the present study, the effects of Tat and MJN110 
treatment on motivated behavior were assessed in the doxycycline(DOX)-inducible Tat 
transgenic mouse model. An operant conditioning task was employed wherein mice learned to 
associate a nosepoke with a sucrose reward. To characterize motivation, breakpoints amongst 
other proxies for motivated behavior were analyzed. Although there were no significant 
differences or interactions between Genotype and Treatment on motivated behavior, we found 
that, on average, Tat(+) subjects appear more motivated than Tat(-) subjects. Additionally, 
MJN110 rescued neuronal damage in Tat(+) subjects but trended towards decreasing dendritic 
ultrastructural integrity in Tat(-) subjects. Interestingly, in MJN110-treated animals, lower levels 
of inflammation are associated with higher measures of motivated behavior and Tat(-) subjects 
display a correlation between lower levels of inflammation and higher measures of motivated 
behavior dependent on treatment duration. These contrasting trends suggest intrinsic differences 
between genotypes conversely modulating inflammatory response to MJN110 treatment. Future 
studies assessing immune tolerance due to chronic Tat exposure, over- enhancement of the eCB 
tone, and levels of differential pro-inflammatory protein expression in genotypes could elucidate 
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Human Immunodeficiency Virus       
 Approximately 38 million people in the world are currently living with Human 
Immunodeficiency Virus (HIV) (UNAIDS, 2020). If left untreated, the two primary subtypes of 
HIV—HIV-1 and HIV-2—can lead to acquired immunodeficiency syndrome (AIDS) (Motomura 
et al., 2008; Nyamweya et al., 2013). Although both subtypes contain several similarities, they 
only share 55% of their genetic sequence (Motomura et al., 2008). The genetic differences 
account for the worldwide distribution of HIV-1, the more pathogenic subtype, while HIV-2 is 
generally confined to West Africa and India (Nyamweya et al., 2013).  
Despite the heavily studied immune consequences of HIV-1, the mechanisms underlying 
the neurocognitive impairments of this virus in the central nervous system (CNS) are less well 
characterized. Currently, there is no effective cure; however, combination antiretroviral therapy 
(cART) has been shown to successfully mitigate HIV-1 driven neurocognitive effects (Ellis et 
al., 2007; McLaurin et al., 2019). cART utilizes a combination of antiretroviral drugs to suppress 
viral replication peripherally, but viral reservoirs remain in the CNS since cART mitigations 
cannot effectively cross the blood-brain barrier (BBB; Ellis et al., 2007). Furthermore, cART 
alone may not be viable for long-term prevention of HIV-associated neurocognitive deficits 
(HAND) since prolonged treatment can cause neurotoxic effects (Yuan & Kaul, 2019).  
Due to cART’s ability to reduce HIV fatality, research has shifted from more serious 
forms of HAND such as HIV-1 associated dementia (HAD) to milder forms of HAND known as 
mild neurocognitive disorder (MND) and asymptomatic neurocognitive impairment (ANI; 
Heaton et al., 2011; Letendre et al., 2009).  
In the post-cART era, HIV-1 disrupts CNS function through neuroinflammation and 
synaptodendritic injury rather than apoptotic methods (Ellis et al., 2007; Fitting et al., 2013; 
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McLaurin et al., 2019). Synaptodendritic injury is characterized by dendritic simplification, 
dendritic beading, aberrant sprouting, and synaptic loss (Ellis et al., 2007; McArthur et al., 
2010). These changes underlying neurocognitive impairment are commonly seen in the 
prefrontal cortex, hippocampus, and striatum (McArthur et al., 2010). Individuals affected by 
HAND display deficits in higher-order cognitive processes such as executive function, working 
memory, and motivation among others (McArthur et al., 2010). These deficits are translated 
from phenotypic alterations in the prefrontal cortex, hippocampus, and the striatum, respectively. 
 
HIV-1 Pathogenesis 
HIV-1 is a retrovirus composed of an outer glycoprotein envelope and two identical 
single strands of RNA in its core (Naif, 2013). The genome codes for structural proteins, 
regulatory proteins, and accessory proteins necessary for HIV-1 replication and pathogenesis. 
HIV-1 preferentially infects host cells expressing CD4 receptors and CXCR4 and CCR5 co-
receptors (Naif, 2013). This includes immune cells such as T-lymphocytes, monocytes, and 
macrophages. To initiate viral entry, the structural envelope glycoprotein, gp160, comprised of 
two subunits, gp120 and gp41, allows the virus to bind to host cell CD4 receptors and CXCR4 or 
CCR5 co-receptors(Ellis et al., 2007; Kovalevich & Langford, 2012; Naif, 2013). Once the virus 
is internalized, reverse transcriptase transcribes the RNA to produce proviral DNA before it can 
be integrated into the host cell genome (Ellis et al., 2007; Kovalevich & Langford, 2012). 
Following genome integration, the virus can replicate and produce viral proteins within the host 
cell.             
 HIV-mediated neurotoxicity occurs once peripherally infected T-cells, monocytes, and 
macrophages penetrate the BBB and release virions and viral proteins (Tat, Nef, Rev, Vpr, 
Gp120) into the CNS (Kovalevich & Langford, 2012). In the CNS, HIV-1 cannot directly infect 
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neurons, however, the virus can infect microglia and astrocytes. Microglia can be productively 
infected, enabling them to produce and release more HIV-1 particles (Lee et al., 1993; Wallet et 
al., 2019). In contrast, latently infected astrocytes are only able to generate viral proteins (Barat 
et al., 2018; Mörner et al., 2003). Neuronal damage primarily occurs through viral protein-
mediated mechanisms. These viral proteins can interact with neurons directly to elicit damage or 
induce neuronal injury indirectly through the activation of glial cells and astrocytes, which 
release proinflammatory cytokines and chemokines (Kovalevich & Langford, 2012). One 
particular viral protein, transactivator of transcription (Tat), is of great interest due to its role in 
both direct and indirect methods of neurotoxicity and the development of HAND. 
 
HIV-1 Transactivator of Transcription (Tat) 
Tat is one of the first transactivator proteins expressed in the HIV-1 genome and drives 
disease progression (Bagashev & Sawaya, 2013; Richter & Palu, 2006). Tat is critical for viral 
transcription (Bagashev & Sawaya, 2013). This regulatory protein is one of the most well-
characterized proteins for inducing direct and indirect HIV-mediated neurotoxicity (Kovalevich 
& Langford, 2012). Since HIV-1 cannot independently penetrate the BBB, Tat enters the CNS 
using two primary methods. Infected immune cells may cross the BBB and release Tat into the 
extracellular space. Alternatively, studies show that Tat released in the periphery can cross the 
BBB without an immune cell carrier (Chang et al., 1997). Once Tat enters the CNS, it can 
directly injure neurons or indirectly infiltrate cells unaffected by HIV-1 (Chopard et al., 2018), 
such as microglia, and induce an inflammatory response which subsequently also injures the 
neuron. The upregulation of glial fibrillary action protein (GFAP) and ionized calcium-binding 
adaptor molecule 1 (Iba-1) can signify increases in neuroinflammation.  
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HIV-1 is considered an inflammatory disease; therefore, extensive literature exists 
detailing the inflammatory responses due to the indirect effects of Tat (Deeks et al., 2013; 
Heaton et al., 2011; Naif, 2013). Notably, the direct effects of Tat are equally detrimental to 
neurons. At high concentrations, Tat contributes to excitotoxicity by interacting directly with 
glutamatergic N-methyl D-aspartate receptors (NMDARs; Li et al., 2008) causing an influx of 
intracellular sodium which then modulates an increase in calcium ions (Fitting et al., 2014). 
NMDARs are further upregulated by increased glutamate release activating AMPA receptors 
(AMPARs; Longordo et al., 2006). Due to ionic imbalances, these elevated levels of sodium and 
calcium have been shown to elicit synaptodendritic structural damage and swelling similar to 
that seen in individuals affected by HAND (Greenwood & Connolly, 2007). 
Additionally, Tat-induced excitotoxicity has also been studied in various rodent models 
and demonstrated resulting in a number of behavioral deficits. Currently, two types of Tat 
transgenic mouse models can replicate the chronic effects of HIV-1 without using the virus itself. 
One model constitutively expresses Tat and resembles the effects of Tat released in the periphery 
(Vogel et al., 1988). This model is primarily used to study Tat’s role in HIV-associated tumor 
development (Corallini et al., 1993). Another model is the Doxycycline (DOX)-inducible Tat 
transgenic mouse model (Bruce-Keller et al., 2008). Here, mice expressing glial fibrillary acidic 
protein (GFAP) promotor-linked tetracycline-controlled transactivator, are crossed with mice 
expressing Tat-linked tetracycline responsive element, allowing for Tat expression in astrocytes 
(Bruce-Keller et al., 2008; Kim et al., 2003). This mimics the effects of chronic HIV in the CNS 
and behavioral phenotypes implicated by HAND. Studies using rodent models have shown that 
Tat exposure can induce region-specific damage in the prefrontal cortex, hippocampus, and 
striatum in a time-dependent manner (King et al., 2006). In the medial prefrontal cortex (mPFC), 
Tat results in overexcitation of pyramidal neurons and astrogliosis (Wayman et al., 2016). This 
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contributes to executive function deficits involving attention and memory seen in HIV-1 infected 
individuals (Wayman et al., 2016). In the hippocampus, Tat induces dendritic spine reduction 
and loss of synaptic integrity similarly resulting in memory deficits (Fitting et al., 2013). The 
loss of dendritic structure can be quantified by the downregulation of microtubule associated 
protein 2 antibody (MAP2), a protein localized to dendrites. Likewise, the excitotoxic effects of 
Tat manifest as dendritic varicosities and spine reduction in the striatum (Bruce-Keller et al., 
2008; Fitting et al., 2014, 2010) contributing to motor memory and motivational deficits (Hahn 
et al., 2015).  
Since no current cART treatment targets the synthesis of Tat, this protein remains present 
in the cerebrospinal fluid (CSF) of HIV-positive individuals (Henderson et al., 2019), further 
demonstrating the need for new HIV therapies that target Tat-induced effects.  
 
Motivational Deficits due to HIV-1       
 Motivational alterations are a common symptom of HIV-1 despite cART treatment 
(Bertrand et al., 2018; Denton et al., 2019). Approximately 30-60% of HIV-infected individuals 
experience feelings of apathy—a reduction of self-initiated behavior which parallels lack of 
motivation (Kamat et al., 2012). Motivational deficits are demonstrated as a reduction in reward 
seeking and goal-directed behaviors in animal models (Bertrand et al., 2018). These deficits can 
be attributed to effects of viral proteins, such as Tat, on the neural systems regulating these 
behaviors (Denton et al., 2019). Notably, the striatum, the primary brain region implicated in 






The striatum is a group of subcortical nuclei in the forebrain involved in movement, 
reward, and motivation. Medium spiny neurons (MSNs), characterized by their medium soma 
and extensive dendritic trees, comprise 95% of the neurons in the striatum (Gokce et al., 2016). 
MSNs are GABAergic inhibitory cells that modulate activity in the striatum. There are two 
primary phenotypes of MSNs: D1-type and D2-type, each expressing D1- or D2-type dopamine 
receptors, respectively (Gokce et al., 2016). The striatum is further subcategorized into two 
subregions, the dorsal and ventral striatum, due to functional distinctions within each area. The 
dorsal striatum contains the caudate and putamen, while the ventral striatum contains the nucleus 
accumbens (NAc). Studies show that both subregions can be affected by Tat. In the dorsal 
striatum, this protein disrupts the BBB and upregulates phagocytic macrophages and microglia - 
jointly a key marker for a latent HIV infection (Leibrand et al., 2017). In the ventral striatum, Tat 
excites D1-type MSNs in a concentration-dependent manner, producing excitotoxic effects 
(Brailoiu et al., 2017). Likewise, higher self-ratings of apathy correlate with a lower volume of 
NAc in HIV-infected individuals (Paul et al., 2005). Although both subregions are affected by 
HIV-1, the ventral striatum appears to play a critical role in motivation. Mediation of reward 
value, the anticipation of future rewards, and the prediction of incentive cues (ICs) are integral 
components of goal-directed behavior and are dependent on the NAc (Corbit et al., 2001; Hart et 
al., 2014). Furthermore, activation of cannabinoid receptor type-1 (CB1R) in the ventral 
tegmental area (VTA), a key input to the NAc, promotes reward seeking behavior (Oleson et al., 
2012). The presence of CB1Rs throughout the striatum and afferent regions (Ferré et al., 2010) 
not only suggests involvement of the endocannabinoid system in modulating motivation related 
processes, but also that it serves a neuroprotective role against the behavioral effects induced by 
Tat. 
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The Endocannabinoid System 
The endocannabinoid system (eCB) is a cell-signaling system formed by endogenous 
cannabinoids, their metabotropic receptors, and metabolic enzymes. Endocannabinoids are 
endogenously produced ligands which predominantly bind to CB1Rs and cannabinoid receptor 
type-2 (CB2R). 2-arachidonoyl glycerol (2-AG) and N-arachidonoylethanolamine 
(anandamide/AEA) are the best-studied endogenous cannabinoids. Monoacylglycerol lipase 
(MAGL) and fatty acid amide hydrolase (FAAH) are the principal metabolic enzymes for 
hydrolyzing 2-AG and AEA, respectively. The eCB system modulates a diverse set of 
physiological processes and has been shown to demonstrate therapeutic potential in neurological 
disorders (Pertwee, 2014; Scotter et al., 2010). Upregulation of CB1Rs is seen in brain regions 
affected by Tat and synaptodendritic damage is often co-localized with these receptors (Jacobs et 
al., 2019; Wu & Thayer, 2020). Tat disrupts the function of the eCB system by impairing CB1R-
mediated inhibition at excitatory terminals (Wu & Thayer, 2020). Notably, neuroprotective 
mechanisms of 2-AG are also dependent upon CB1Rs (Xu et al., 2017). Rather than direct 
administration of 2-AG, which is rapidly hydrolyzed by MAGL in vivo (Saario et al., 2004), 
inhibition of the degradation of 2-AG with a MAGL inhibitor displays more promising 
neuroprotective effects against Tat-mediated excitotoxicity given the longer duration in which 2-
AG is upregulated.          
 In addition to therapeutic applications, the eCB system is involved in the neural 
mechanisms of motivational processes. Along with reward-seeking behavior, determination of 
hedonic value and sensitivity to natural rewards are primarily mediated through CB1Rs 
(Maccioni et al., 2008; Oleson et al., 2012). Furthermore, upregulation of 2-AG following 
administration of MAGL inhibitor JZL184 has been shown to increase breakpoints, the point at 
which the mice stops responding to the reinforcer, and decrease latencies to respond in 
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progressive ratio tasks (Gianessi et al., 2020; Oleson et al., 2012). The novel MAGL inhibitor 
MJN110 has been studied in similar motivational contexts (Feja et al., 2020).   
  
MJN110          
 MJN110 is a tertiary N-Hydroxysuccinimidyl (NHS) carbamate which can irreversibly 
inhibit serine hydrolases such as MAGL. This compound is more specific and potent to MAGL 
than previous inhibitors (Niphakis et al., 2013). Despite documented success with JZL184, a 
PNP carbamate, this particular inhibitor is problematic due to its cross-reactivity with FAAH. 
Dual inhibition of MAGL and FAAH has been shown to induce catalepsy and drug-dependence 
in mice due to increases in both 2-AG and AEA levels (Long et al., 2009). Thus, MJN110 may 
serve as a more efficacious MAGL inhibitor since it successfully increases 2-AG levels in the 
brain without upregulating FAAH or producing the severe cannabimimetic effects seen with 
direct CB1R agonists (Niphakis et al., 2013). In addition, MJN110 increases responding to 
incentive reward-predictive cues, through CB1R activation by 2-AG demonstrating its ability to 
influence motivational properties (Feja et al., 2020).  
               
Motivated Behavior Paradigm       
 Motivational alterations are often tested using operant conditioning (instrumental 
learning) tasks (Bertrand et al., 2018). Operant conditioning is a method of learning which 
occurs through repeated reinforcement with either rewards or punishments. Following the initial 
acquisition of goal-directed behavior, this response is maintained by motivational processes 
(Koob et al., 2009; Staddon & Cerutti, 2003). Operant conditioning is commonly utilized in 
animal studies to assess the reinforcing efficacy of drugs of abuse and how motivated the mice is 
to obtain the drug (Arnold & Roberts, 1997; Dayan & Balleine, 2002). Alongside drugs of abuse, 
 12 
other common reinforcers, such as food and water, also generate positive hedonic value. In 
motivated behavior paradigms, mice are initially trained on fixed-ratio 1 (FR-1) schedules for 
positive reinforcement where the reinforcer is delivered after every response. Once mice learn 
and maintain the response, they advance to a progressive ratio (PR) task wherein the number of 
responses required for delivery of the reinforcer is increased following each subsequent response 
(Bertrand et al., 2018). This method has proven to be advantageous to evaluate motivation 
(Arnold & Roberts, 1997; Hodos, 1961). Motivation can be characterized by comparing the total 
number of responses, response latencies, and breakpoints (Koob et al., 2009; Staddon & Cerutti, 
2003). In light of the success of operant conditioning tasks using MJN110 to characterize effects 
on motivation, this paradigm serves as a good fit for our current study (Feja et al., 2020). While 
PR tasks have been traditionally performed on rats, previous studies confirm that this is an 
equally valid operant paradigm for mice (Sharma et al., 2012; Vaughan et al., 2006). 
        
Our Proposed Study          
 The present study aims to address the questions raised from a previous study conducted 
by League et al. (under review). In a preliminary olfactory discrimination flexibility (ODF) task 
to assess the effects of Tat on PFC function, it was found that Tat(+) mice displayed a higher 
initial acquisition rate to obtain an odorant reward compared to Tat(-) mice (League et al., under 
review). Since previous literature indicates that Tat(+) animals exhibit deficits in cognitive or 
memory-related tasks (Fitting et al., 2013; Wayman et al., 2016), it was initially hypothesized 
that Tat(+) groups would show decreased performance. Interestingly, in the reversal training 
phase, Tat(+) mice treated with MJN110 displayed a lower reversal acquisition rate towards the 
new reward cue although MJN110 had effectively increased 2-AG levels in the pFC, 
hippocampus, and striatum. The reward-related nature of the ODF task and upregulation of 2-AG 
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in the striatum, suggest a potential motivational factor present in Tat(+) mice later modulated by 
MJN110 administration.         
 Although previous literature states that Tat is involved in downregulating motivational 
processing (Bertrand et al., 2018) and activation of the eCB system induces restorative 
effects(Pertwee, 2014; Scotter et al., 2010), the ODF task results did not adhere to these ideas. 
Thus, these findings prompted us to investigate the effects of HIV-1 Tat and MJN110, both 
independently and through their interactions, on motivated behavior in the striatum. To study 
these effects, we will test whether the expression of Tat and administration of MJN110 will 
affect breakpoints in an operant conditioning paradigm using a doxycycline-induced HIV-1 Tat 
transgenic mouse model. We hypothesize that Tat(+) mice will have lower breakpoints and that 
MJN110 will mitigate these changes. We also expect MJN110 to reduce levels of Tat-associated 
neuroinflammation, observed through reduction Iba-1 in microglia, and dendritic damage, 
through upregulation of MAP2, in the striatum. The broader goal of this project is to explore 
potential therapeutics by leveraging the endocannabinoid system to combat the neurotoxic 
effects of latent HIV infection in an effort to address both neurocognitive deficits associated with 










Materials and Methods 
Subjects           
 This experiment used GFAP driven, DOX-inducible, brain specific HIV-1 IIIB Tat1-86 
transgenic female mice (N = 36) developed on a hybrid C57BL/6J  background (Bruce-Keller et 
al., 2008; Chauhan et al., 2003). To induce Tat protein expression, formulated 6 mg/g DOX 
chow (6000 ppm, TD.09282, Envigo, NJ, USA) was fed to the experimental mice (n = 18) 
expressing both the GFAP-rtTa and TRE-tat genes [Tat(+) mice]. The same DOX diet was given 
to the remaining control mice (n =18) which expressed the GFAP-rtTA gene but not the TRE-tat 
gene [Tat(-) mice]. All mice were genotyped 7 - 14 days after weaning to confirm Tat 
expression.  
Subjects were bred and kept in Davie Hall Animal facility. Mice were either single or 
group-housed (2-3 mice per cage) and provided DOX chow and water ad libitum. Both Tat(-) 
and Tat(+) mice were fed DOX for 4 months prior to and throughout behavioral testing to ensure 
and maintain Tat expression. Mice were kept in a 12 hour reversed light/dark cycle and 
experiments were run during the first half of their dark cycle (9:00 am - 3:00 pm). All 
experimental procedures were approved by the University of North Carolina at Chapel Hill 
Institutional Animal Care and Use Committee (IACUC) and conducted per the NIH Guide for 
the Care and Use of Laboratory Animals. 
 
Treatment 
Subjects were separated into 4 groups based on genotype [i.e., Tat(+) or Tat(-)] and 
treatment (i.e., Vehicle or MJN110). Treatment was randomly assigned and counterbalanced 
across mice allowing for 9 mice per group [i.e., Tat(+)/Vehicle, Tat(-)/Vehicle, Tat(+)/MJN110, 
Tat-/MJN110]. The control saline-based vehicle injection was prepared with ethanol (Decon 
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Laboratories, #64174), Kolliphor (Sigma-Aldrich, #C5135), and 0.9% sodium chloride (Braun 
Medical, J8K944) in a 1:1:18 ratio (Niphakis et al., 2013). For the MJN110 injection, 1 mg/kg 
MJN110 was dissolved in a saline vehicle solution as previously described. Injections were 
administered subcutaneously (10 uL/g body mass) 2 weeks prior to behavior testing and 
continued through behavior and until mice were sacrificed for brain analyses. During the 
behavioral testing window, solutions were injected approximately 2 hours before experiments. 
Similarly, when brains were harvested after behavioral testing was completed mice received 
Vehicle or MJN110 injections 2 hours prior sacrifice. 
 
Apparatus 
 Behavioral testing was performed in a dark room with red fluorescent lighting and white 
noise at 80 db. 16 standard mouse operant chambers (MED Associates ENV-307 W) were 
housed in individual sound-attenuating cubicles (MED Associates ENV-022MD) to reduce light 
and sound interference. Each chamber contained a single nose-poke hole adjacent to a reward 
hole providing access to a liquid dipper (MED Associate ENV-302W-S) with the 25% sucrose 
solution reward controlled by MED-PC computer interface software. Upon the start of the trial, 
dippers were released into the sucrose solution and yellow light illuminated the nosepoke area.  
 
Behavioral Procedure 
Behavioral testing included three phases: Magazine Training, Fixed-Ratio-1 (FR-1) 
Shaping, and the Progressive Fixed Ratio (PFR) Test (Figure 1). Once the mice were habituated 
to the testing environment, they underwent magazine training, wherein they were familiarized 
with the sucrose delivery mechanism which delivered sucrose solution. Then they were trained 
on the FR-1 schedule to associate the nose-poke response with the reinforcer. After mice earned  
 16 
≥ 20 reinforcers for 2 consecutive days during FR-1 shaping sessions, they were advanced to a 
single PFR test to determine the breakpoint. Mice were advanced through each phase using an 
individual advancement strategy to ensure equal training and to prevent overtraining. Magazine 
training and FR-1 shaping sessions terminated after 1 hour, while the PFR test terminated after 3 
hours or after mice did not earn a reinforcer for 20 consecutive minutes, whichever occurred 
first.             
 Due to the limited number of operant boxes, mice were randomly assigned to one of three 
squads (A, B, and C). In each squad, mice were randomly assigned to one of the 16 operant 
boxes. Squads were run immediately after one another and injections were timed to 2 hours 
before the respective squad’s testing time. Towards the end of the experiments when fewer mice 
were run in each squad, all remaining mice were transferred to squad B to ensure equal time shift 
either forward or back.  
Habituation. Mice were handled for 2-3 minutes daily during the two-week injection 
period prior to behavioral testing. Weights were recorded weekly until the injection period and 
were recorded daily afterward. Water in home cages was replaced with 10% sucrose 3 days prior 
to habituation and 20% sucrose 2 days prior to habituation. Water in home cages was returned 
the day before habituation to increase salient motivation towards sucrose reinforcer.  
Mice were habituated to the testing environment with operant chambers and white noise 
powered on but all other components inactive (30 minutes) for 1 day. Sucrose solution was not 
made available during habituation.  
Magazine Training. Following habituation, mice were placed in the operant chambers 
with chambers set to administer the sucrose solution reinforcer every 30-45 seconds with a 20 
second access time. Additionally, a nose-poke response triggered sucrose solution access on an 
FR-1 schedule to reward the learned association. If responses by the end of trial ≥ 1, mice were 
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advanced to FR-1 shaping sessions. If not, magazine training was repeated until responses ≥ 1. 
 Fixed-Ratio-1 (FR-1) Shaping. Mice were placed in the operant chambers with 
chambers set to administer sucrose solution only upon nose-poke response. If responses by the 
end of session ≥ 20, the mice had met the criteria. If responses made ≥ 20 for 2 consecutive days, 
the mice were advanced to the PFR test session. If no response was made for 3 consecutive 
sessions, the mice underwent magazine training and returned to FR-1 shaping sessions the 
following day. Number of shaping sessions (days spent in FR-1 schedule) were recorded to 
measure the task acquisition rate. The average number of RF earned on days when criteria was 
met (≥ 20 RF) was also recorded as an early indication of motivation and response vigor.   
  Progressive Fixed Ratio (PFR) Test. Mice were placed in the operant chambers with 
chambers set to administer sucrose solution upon n+1 responses, beginning at 0 (where n = 
number of responses in the previous trial; i.e., 1,2,3, etc.). To assess motivation and incentive 
salience, the breakpoints were recorded and analyzed.  Total nosepokes during the PFR session 
and total time in PFR session were recorded as gross measures to ultimately calculate response 
vigor from the total nosepokes per minute. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
Immunohistochemistry (IHC)         
  Mice underwent isoflurane-induced anesthesia and were sacrificed via rapid 
decapitation. The right hemisphere was dissected and snap frozen for Ultraperformance Liquid 
Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS; data not presented here as it is 
ongoing). For IHC, the other (left) hemisphere of the brain was dissected and post-fixed in a 15 
mL conical tube filled containing 12 mL 4% paraformaldehyde (PFA). The conical tube 
containing the PFA suspended brain was placed on a rocker at room temperature and moved to a 
rocker at 4° C after 24 hours. The brains were washed with 1X phosphate buffer solution (PBS) 
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in three 20-minute intervals and stored in 30% sucrose solution for 24 hours at 4° C. Brains were 
embedded with Tissue-Tek O.C.T compound in disposable embedding molds and frozen using 
dry ice before being stored at -80° C until sectioning. Sagittal sections were collected using a 
Leica CM300 cryostat (Leica, Deerfield, IL) at −21° C to a 30 um thickness. For each brain, 5 
sections which were representative of the dorsal and ventral striatum were collected in a 12-well 
plate and stored at 4° C until staining.         
 All IHC steps were performed according to League et al. (under review). 3-4 sections 
containing the striatum according to the Allen Brain Atlas (2004) were selected for each subject. 
To summarize, tissue was permeabilized with 0.5% H2O2 solution for 30 minutes, followed by 
1% H2O2 for 1 hour, and 0.5% H2O2 solution for 30 minutes. Then, tissue was treated with a goat 
blocking solution for 1 hour (3% normal goat serum, 0.5% TritonX100 in 1X PBS) and 
incubated with primary antibodies mixed into goat blocking solution against MAP2 (Millipore, 
MAB378; 1:500) and Iba-1 (Wako #019-19741, 1:500) and stored at 4 ºC.   
 Following 48 hours, sections were exposed to secondary antibodies conjugated to anti-
rabbit Alexa 488 for MAP2 (ThermoFisher Scientific, O-6380, 1:1000) and anti-mouse Alexa 
594 for Iba-1 (ThermoFisher #A11032; red; 1:500) in goat blocking solution for 1 hour. To stain 
cell nuclei, tissue was incubated in Hoechst dye (ThermoFisher Scientific, #H3570) for 3 
minutes and distilled with water before mounting on SuperFrost Plus glass slides (Fisher 
Scientific, Pittsburgh, PA). Vectashield Antifade Mounting Medium (Vector Laboratories, 
#H100010) was applied to coverslips before sealing the slides.   
                          
Imaging            
 A Zeiss LSM laser scanning confocal microscope (Zeiss, Thornwood, NY) was used to 
obtain single-plane images using a 20x objective lens and the ZEN 2018 blue Edition software 
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(Carl Zeiss, Inc., Thornwood, NY). One image was captured for each tissue section (3-4 sagittal 
sections spaced 30 um apart) focusing on the dorsal striatum (Figure 3A). ImageJ software was 
used to quantify the mean fluorescence intensities of MAP2 staining as a measure of dendritic 
structural integrity. Microglia cell bodies immunolabeled with Iba-1 as a measure of cellular 
inflammatory response and were counted by two experimenters blinded to genotype and 
treatment (Vehicle or MJN110). Internal consistency and reliability of the Iba-1 cell counts 
between the two experimenters was measured using Cronbach’s ɑ (ɑ = 0.875). The strong ɑ 
value allowed us to average the data from both experimenters as a representation of the Iba-1 cell 
counts. Values for MAP2 intensity and Iba-1 cell counts were averaged across sections per 
subject before analysis.       
             
Statistical Analysis          
 All descriptive statistics were conducted using GraphPad Prism (GraphPad Prism, 
Version 9.0.0 for MacIntosh). Behavior analysis was reported as means (M) ± standard error of 
mean (SEM). One-way or two-way analysis of variance (ANOVAs) with Treatment (Vehicle or 
MJN110) and Genotype [Tat(-) or Tat(+)] as between-subjects factors were run, followed by 
Tukey’s post hoc tests where necessary. IHC analysis was similarly conducted, followed by 
Bonferroni post-hoc tests. The relationship between behavior results (e.g., breakpoints and 
number of shaping sessions) and IHC measures (e.g., MAP2 and Iba-1) were evaluated using the 
Pearson correlation coefficient and fit to a linear regression model. The alpha level of p <0.05 




                                                              Results                                                       
Motivated Behavior Paradigm        
 Two-way ANOVAs with Treatment (Vehicle, MJN110) and Genotype [Tat(-), Tat(+)] as 
factors displayed no significant interactions between or effects of Treatment and Genotype on 
the number of shaping sessions [Figure 2A; F(1, 30) < 1.0, p = 0.673], or on the average number 
of reinforcers earned on days when criteria was met [Figure 2B; F(1, 30) < 1.0, p = 0.992]. A 
two-way ANOVA performed with data from the PFR test session revealed no significant 
interactions between Treatment and Genotype on breakpoints [Figure 2C; F(1, 30) < 1.0, p = 
0.981], total time spent in session [Figure 2D; F(1, 30) < 1.0, p = 0.554], total nosepokes 
[Figure 2E; F(1, 30) <1.0, p = 0.912], or nosepokes per minute [Figure 2F; F(1, 30) = 1.05, p = 
0.315]. Likewise, no significant effect of Treatment or Genotype was found on these dependent 
variables (all p’s > 0.05).           
 Although no significant treatment or genotype differences were found across behavior 
variables, certain patterns were observed in the data. MJN110-treated animals trended toward 
higher breakpoints (Figure 2C; M = 16.72, SEM = 0.72) compared to vehicle-treated subjects 
(Figure 2C; M = 13.22, SEM = 0.78; p = 0.149) suggesting that MJN110 may alter proxy for 
motivation during the PFR task independent of genotype. Additionally, Tat(+) subjects (Figure 
2D; M = 103.50, SEM = 14.67) trended towards greater total time in the PFR session relative to 
Tat(-) subjects (Figure 2D; M = 80.06, SEM = 5.40; p = 0.140).    
             
Immunohistochemistry (IHC)         
 IHC was utilized as an ex vivo measure to assess the neuronal effects of Tat and MJN110 
and to visualize potential structural changes resulting from Tat expression or drug treatment. 
MAP2 fluorescence intensity and Iba-1 cell counts served as measures of neuronal cytoskeleton 
 21 
integrity and inflammatory response driven by microglia, respectively. A two-way ANOVA for 
MAP2 revealed no significant effects of Treatment [Figure 3B; F(1, 30) < 1.0, p = 0.889] or 
Genotype  [Figure 3B; F(1, 30) = 3.55, p = 0.070], but did display a significant interaction 
between Treatment and Genotype [Figure 3B; F(1, 30) = 14.25, p < 0.001]. Bonferroni's test of 
multiple comparisons indicated that that vehicle-treated Tat(+) mice (Figure 3B; M = 16.40, 
SEM = 1.38) displayed significantly decreased neuronal ultrastructural integrity compared to 
vehicle-treated Tat(-) mice (Figure 3B; M = 31.00, SEM = 3.56; p = 0.002). Although MJN110 
treatment did not significantly modify this effect, Tat(+) mice (Figure 3B; M = 25.76, SEM= 
2.85) trended towards higher MAP2 expression while Tat(-) mice (Figure 3B; M = 20.86, SEM 
= 1.38) trended towards lower MAP2 expression compared to vehicle treatment (Figure 3B; M = 
16.36, SEM = 1.38; p = 0.093; M = 31.00,  SEM = 3.56; p = 0.057 for Tat(+) and Tat(-) mice 
respectively). In contrast, a two-way ANOVA for Iba-1 revealed no significant effect of 
Treatment [Figure 3C; F(1, 30) < 1.0, p = 0.404] or Genotype [Figure 3C; F(1, 30) < 1.0, p = 
0.957], nor an interaction between the two factors [Figure 3C; F(1, 30) < 1.0, p = 0.916].  
   
Correlations between Behavior and Immunohistochemistry    
 No significant correlations were found between behavioral measures and MAP2 
expression (data not shown; all p’s > 0.05). However, in MJN110-treated animals, a significant 
negative correlation was found between breakpoints and Iba-1 expression (Figure 4D; 
r = −0.603, p = 0.010), such that higher breakpoints were associated with decreased markers for 
microglia. 30% of variation in breakpoint scores during the PFR test was attributable to striatal 
Iba-1 cell counts. In MJN110-treated animals, a significant negative relationship was also 
observed between PFR nosepokes per minute and Iba-1 expression (Figure 4F; r = -0.522, p = 
0.032). 27.2% of variation in nosepokes per minute during the PFR task was attributable to 
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striatal Iba-1 cell counts. In Tat(-) subjects, a significant negative correlation was found between 
the number of shaping sessions and Iba-1, indicating a greater number of days on the FR-1 
schedule was associated with decreased striatal microglia counts (Figure 4B; r =  -0.599, p = 
0.011). 35.9% of variation in number of shaping sessions was attributable to striatal Iba-1 cell 
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               Discussion      
 The present study reports the effects of HIV-1 Tat and MJN110 on motivated behavior in 
the DOX-induced Tat transgenic mouse model. Designed as a follow-up study to a previous 
olfactory discrimination flexibility (ODF task; assessing behavioral flexibility) conducted by 
League et al. (under review), this project aimed to further assess how motivation is affected by 
the presence of Tat and treatment with MJN110 in the striatum. An operant conditioning task 
was utilized to evaluate motivation across genotype and treatment groups (Figure 1). 
Motivational deficits such as apathy are common in HIV-1 infected individuals and a prominent 
symptom of HAND (Bertrand et al., 2018; Denton et al., 2019). These deficits can be attributed 
to Tat and other residual viral proteins (Denton et al., 2019); therefore, it was hypothesized that 
the Tat(+) subjects would be less motivated than the Tat(-) subjects, phenotypically translating to 
lower breakpoints. Due to the known protective effects of 2-AG upregulation against neural 
damage induced by Tat (Xu et al., 2017), it was also hypothesized that MJN110-treated animals 
would have higher breakpoints. Neither hypothesis is heavily supported by the results because 
there were no significant differences found between these groups across measures of motivated 
behavior including, but not limited to, breakpoints [Figure 2C; i.e. number of shaping sessions 
(Figure 2A), average reinforcers earned when criteria are met (Figure 2B), and the number of 
nosepokes per minute in PFR session (Figure 2F)].      
 Results from the IHC analysis showed that vehicle-treated Tat(+) subjects expressed 
significantly lower levels of MAP2 than vehicle-treated Tat(-) subjects (Figure 3B). MAP2 
intensity serves as a marker for synaptodendritic damage (Ellis et al., 2007), such that decreased 
expression signifies more neuronal injury. These data recapitulate those which establish that Tat 
induces dendritic damage amongst other morphological changes (Fitting et al., 2014; Li et al., 
2008). While MJN110 did not significantly alter MAP2 expression across genotypes, treatment 
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did appear to mitigate some neuronal damage, shown through a higher average MAP2 intensity 
for Tat(+) subjects (Figure 3B). This rescue effect could also account for the higher average 
breakpoints in the Tat(+) subjects since this is reversing the physiological damage seen in the 
control group (Figure 2C). Conversely, MJN110-treated Tat(-) subjects trended towards a 
decrease in MAP2 expression compared to vehicle-treated Tat(-) subjects (Figure 3B; p = 
0.057). As previous studies primarily discuss restorative effects of the eCB system in treating 
neurodegeneration (Pertwee, 2014; Scotter et al., 2010), this opposing effect should be further 
investigated. While MJN110 showed restorative effects in Tat(+) animals, perhaps overactivation 
of the eCB system through MJN110 administration was deleterious in Tat(-) mice. A congruent 
trend was seen in League et al. (under review) using an ODF task in which MJN110 similarly 
worsened behavior in Tat(-) but not Tat(+) subjects by decreasing reversal task acquisition rates. 
Although the mentioned ODF task involves learning mechanisms centered in the PFC rather than 
the striatum (League et al., under review), these concurring patterns between the studies may be 
pointing to differential effects specific to each genotype.   
 Neuroinflammation is characteristic of chronic HIV-1 models and Tat expression from 
latently infected microglia (Deeks et al., 2013; Heaton et al., 2011; Naif, 2013), however, no 
significant differences in Iba-1 expression were found between groups (Figure 3C). In Tat 
transgenic mice, short-term exposure to DOX has been shown to upregulate microglia in the 
CNS during an inflammatory response (Fitting et al., 2010; Gonek et al., 2018), however, recent 
studies speculate that long-term exposure can result in immune tolerance due to compensatory 
responses from sustained inflammatory activity (Hermes et al., 2020). A study by Hermes et al. 
(2020) found that 3-month Tat exposure reduced levels of proinflammatory cytokines and 
chemokines in the striatum. Despite inflammation reduction from original levels, low-grade 
inflammation continues as a vital component of immune tolerance (Rogovskii, 2020). Given that 
 25 
the subjects in this study were provided DOX chow for 4 months, the similarities in low Iba-1 
cell counts across genotypes could be the product of Tat-induced immune tolerance. 
Furthermore, subjects from League et al. (under review) were also chronically exposed to DOX 
chow for 3 months and displayed similar behavior trends. Since chronic DOX exposure can only 
affect the mice expressing both the GFAP-rtTa and TRE-tat genes [i.e. Tat(+) mice], a reduction 
in immune response may mitigate the physiological effects commonly seen with 
neuroinflammation such as memory, learning, and motivational deficits (Ellis et al., 2007); thus 
allowing the Tat(+) subjects to be more motivated, on average, than the Tat(-) subjects.    
Correlations were run as a final measure to relate behavioral findings to IHC pathology. 
A significant negative correlation observed between Iba-1 cell counts and measured proxies for 
motivation in MJN110-treated animals [e.g. breakpoints (Figure 4D) and the number of 
nosepokes/min (Figure 4F)] indicates that decreased Iba-1 cell counts are associated with 
increased measures of motivated behavior. Overall, MJN110-treated animals require less time, 
on average, to reach the PFR task compared to the vehicle-treated animals (Figure 2A; i.e fewer 
shaping sessions). Within the Tat(-) group, there is a significant negative relationship between 
Iba-1 cell counts and the number of shaping sessions such that subjects requiring more shaping 
sessions have lower Iba-1 cell counts (Figure 4B). Subjects who learned the operant task more 
quickly were consequently administered MJN110 for fewer days, thus extended duration of 
MJN110 treatment in slower learning subjects may have had a functionally significant effect on 
Iba-1 expression in the tissue. Due to the anti-inflammatory properties of eCBs (Jacobs et al., 
2019; Pertwee, 2014; Scotter et al., 2010), it’s possible that the MJN110-induced upregulation of 
2-AG produced similar effects in a time-dependent manner. Interestingly, this effect is only seen 
in Tat(-) subjects, as treatment duration is not associated with inflammatory response in Tat(+) 
subjects (Figure 4B). MJN110 treatment appears to depend on treatment duration in Tat(-) 
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subjects but is efficacious in Tat(+) subjects, regardless of treatment duration, aligning with the 
aforementioned rescue effects in MAP2 expression (Figure 3B) and further supporting the 
argument that genotype is driving these morphological and behavioral differences.Treatment 
effects are another avenue for exploration since the expected therapeutic potential of the eCB 
system was not showcased in this study. One potential reason for this is that the MJN110 dose (1 
mg/kg) may not have been high enough to produce any significant behavioral changes. Higher 
treatment doses (i.e. 5 mg/kg and 10 mg/kg) are efficacious in motivational studies (Feja et al., 
2020) but excess 2-AG circulation can lead to locomotor deficits (Ignatowska-Jankowska et al., 
2015). Alternatively, the systemic administration of MJN110 could target other brain regions 
beyond the striatum. According to a case report in which a patient was presented with a FAAH 
pseudogene, an overactive eCB system led to memory deficits primarily through the 
upregulation of AEA (Habib et al., 2019). We have previously seen that MJN110 administration 
significantly increased levels of AEA along with 2-AG in the PFC, a brain region implicated in 
performing executive functions (League et al., under review). Although the operant conditioning 
task was primarily employed to elucidate motivation and reward-seeking behavior, the 
compounded disruption of neural circuits necessary for learning and memory from both Tat-
mediated excitotoxicity (Fitting et al., 2013; Wayman et al., 2016) and exaggerated eCB tone 
could consequently affect reward circuitry.       
Future directions may aim to quantify eCB levels to not only confirm MJN110 induced 
upregulation of 2-AG but to also examine levels of AEA that could be attributed to an enhanced 
eCB tone and memory deficits (Habib et al., 2019). It would be beneficial to examine 
morphological changes in the ventral striatum since it is heavily involved in reward-seeking 
behavior and its role in operant conditioning (Corbit et al., 2001; Oleson et al., 2012). Additional 
imaging of the hippocampus and mPFC would allow us to compare patterns in interrelated 
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regions that are collectively affected by Tat (Fitting et al., 2013; King et al., 2006; Wayman et 
al., 2016). Lastly, quantification of CB1R density is beneficial to pinpoint brain regions with the 
greatest 2-AG upregulation and thus the greatest effects of MJN110. A comparison between 
these results and the current behavioral data could reveal trends and patterns beyond what is seen 
in this study.           
Despite the success of cART in reducing the prevalence of severe forms of HAND, 
persistent neuroinflammation, due to chronic low levels of HIV-1 protein exposure (Hahn et al., 
2015), accounts for enhanced neuronal injury and the consequential behavior deficits 
(Kovalevich & Langford, 2012). The DOX-inducible Tat transgenic mouse model mimics the 
effects of a latent HIV-1 infection by eliciting a Tat-induced inflammatory response in the CNS 
(Bruce-Keller et al., 2008). Although this extension to (League et al., under review) did not 
elucidate significant effects of genotype [Tat(-), Tat(+)] or treatment (Vehicle, MJN110) on 
motivated behavior, it did reveal an intrinsic difference between the two genotypes beyond Tat 
expression driven by inflammatory responses. Given recent results from brain tissue of subjects 
from the present study and analyzed using Ultraperformance Liquid Chromatography-Tandem 
Mass Spectrometry (UPLC-MS/MS), this could be due to Tat-driven increases in 
proinflammatory proteins (sharing arachidonic acid (AA) as a precursor) in the hippocampus 
(data not shown). AA is a downstream inflammatory metabolite of 2-AG, and hydrolysis of AA 
produces other proinflammatory metabolites such as prostaglandins and eicosanoids (Grabner et 
al., 2016). Throughout this study, we see contrasting trends in how MJN110 affects Tat(-) and 
Tat(+) subjects, and these varying behavioral patterns could be the result of differential protein 
expression and associated cellular activity between genotypes. In future analyses, this could be 
probed further by experimenting with varying doses of MJN110 to see if dose-dependent 
changes in expression of these proinflammatory proteins is evident, and whether the effect of 
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genotype is altered at different doses. Our broader goal is to learn more about the various 
inflammatory responses at play in these different physiological and pathological conditions 
produced by the DOX-inducible Tat transgenic mouse model. Ultimately, we aim to continue 
characterizing the effects of Tat in inflammatory responses to determine viable methods of 






















In conclusion, the results of this study displayed no significant differences or interactions 
between Genotype [Tat(+), Tat(-)] and Treatment (Vehicle, MJN110), for any measured proxies 
for motivated behavior. Overall, Tat(+) subjects displayed higher averages for measures of 
motivated behavior which could be attributed to immune tolerance as a result of chronic 
doxycycline exposure. MJN110 displayed a rescue effect against dendritic damage to Tat(+) 
subjects which were not apparent in Tat(-) subjects. Furthermore, in MJN110-treated subjects, 
there is a significant relationship between reduced neuroinflammation and higher measures of 
motivated behavior, but this effect is dependent on treatment duration in Tat(-) animals whereas 
Tat(+) subjects experience a more leveled effect. These results suggest that 2-AG upregulation 
may have distinct mechanisms of action based on genotype. The presented data led us to shift 
our focus from simply delineating the effects of Tat and MJN110 on motivated behavior in the 
striatum to examining how the variation in inflammatory response between genotypes can 
subsequently affect motivated behavior. Future studies exploring levels of pro-inflammatory 
protein expression in the regions of interest are necessary to determine whether the noted 
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Figure 1. Timeline for motivated behavior paradigm. Mice were provided DOX chow in home 
cages for 4 months to induce Tat expression. Vehicle and MJN110 injection administration 
began 2 weeks prior to experiment and continued throughout behavioral testing. Mice were 
habituated to behavioral apparatus for 30 minutes one day prior to behavioral testing. Mice 
underwent magazine training for 1 hour and advanced to FR-1 schedule if responses  ≥ 1. During 
1 hour FR-1 shaping sessions, mice were advanced to the 3 hour PFR test session if responses 
made ≥ 20 for 2 consecutive days otherwise they returned to magazine training. All advancement 
occurred on an individual advancement strategy. 
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Figure 2. Details effects of genotype and treatment on behavioral response for motivated 
behavior paradigm. (A) No significant differences were observed between groups in the number 
of days spent on FR-1 schedule. (B) No significant differences in average reinforcers earned on 
days when criteria was met (RF ≥ 20) (C) No significant differences were observed in 
breakpoints between groups during PFR task. (D) No significant differences between groups in 
total time spent in PFR task. (E) No significant differences between groups in total nosepokes 
during PFR task. (F) No significant differences between groups in total nosepokes per minute 
during PFR task. Data is portrayed as mean ± SEM. Statistical significance was determined using 
ANOVA with an alpha level of p < 0.05 considered as significant for all statistical tests. 
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Figure 3. Displays immunohistochemistry data on MAP2 and Iba-1 expression. (A) 20x 
magnification image of dorsal striatum shows staining for MAP2 (green) and Iba-1 (red) overlaid 
on Hoechst (blue). MAP2 expression is quantified by calculating the average fluorescence 
intensity per pixel. Iba-1 expression is quantified by counting individual microglia with high 
fluorescence intensity. (B) MAP2 expression was significantly lower in vehicle-treated Tat(+) 
subjects than vehicle-treated Tat(-) subjects. (C) No significant differences in Iba-1 expression 




Figure 4. Displays Pearson correlations between Iba-1 expression and behavioral response. (A) 
No significant relationship was found between breakpoints and Iba-1 expression across 
genotypes. (B). A significant negative relationship was found between breakpoints and Iba-1 
expression in Tat(-) mice. (C) No significant relationship was found between the number of 
nosepokes per minute during the PFR session and Iba-1 expression across genotypes. (D) A 
significant negative relationship was found between breakpoints and Iba-1 expression in 
MJN110-treated mice. (E) No significant relationship was found between the number of shaping 
sessions and Iba-1 expression across treatment groups. (F) A significant negative relationship 
was found between the number of nosepokes per minute during the PFR session and Iba-1 
expression in MJN110-treated mice. 
 
 
 
